Evidence-first longevity reporting
Fifty-five source-reviewed stories explain what human studies, early trials, biomarkers and laboratory research can—and cannot—tell us about healthier aging.
Browse all storiesSmoking cessation & mortality
Two large observational analyses found substantially higher mortality with current cigarette smoking and lower excess mortality after stopping. The estimates describe populations; they do not promise a particular person extra years.
Read the analysis
Essential evergreen guide
Start with the foundations before the hacks. See what human evidence supports—and where claims about slower aging or added lifespan get ahead of the science.
Original AI-assisted editorial illustration · not scientific evidence
Read all 10 evidence-first foundations
Named human authorship
Meet the author responsible for MoreYears.news sourcing, evidence boundaries, and published articles.
Latest stories
Each story names the studied population, outcome, limits, safety context and sources—without turning a promising signal into a longevity promise.
Health & function
In 5,451 older adults at increased fall-injury risk, a nurse-led multifactorial strategy did not significantly reduce the first adjudicated serious fall injury versus enhanced usual care. A secondary self-reported fall-injury outcome differed.
Human serious fall injuries · large pragmatic cluster-randomized trialRead the story
Health & function
Among 317 selected older adults at high risk of falls, the LiFE program integrated balance and strength activities into everyday routines and reduced the self-reported fall rate versus sham gentle exercise over 12 months.
Human self-reported falls and function · small randomized trialRead the story
Health & function
In 670 selected community-dwelling older adults at high risk of falling, a therapeutically tailored Tai Ji Quan program reduced falls over 24 weeks versus stretching and multimodal exercise.
Human fall incidence · three-arm randomized trialRead the story
Everyday foundations
Among adults at high risk for type 2 diabetes, the DPP lifestyle and metformin groups still had lower cumulative diabetes incidence after 15 years. The randomized groups did not differ significantly in the study’s aggregate microvascular outcome.
Human diabetes incidence and microvascular outcomes · long randomized follow-upRead the story
Everyday foundations
In 5,145 adults with type 2 diabetes and overweight or obesity, intensive lifestyle intervention produced greater sustained weight loss and improved several risk factors. It did not significantly reduce the trial’s primary cardiovascular outcome.
Human cardiovascular events and function · large randomized trialRead the story
Health & function
In 10,251 adults with type 2 diabetes and high cardiovascular risk, an intensive multi-drug strategy targeting near-normal glycated hemoglobin did not significantly reduce the primary cardiovascular outcome and increased all-cause mortality.
Human cardiovascular events, mortality and safety · large randomized trialRead the storyExplore by topic
Plain-language categories organize the reporting. They do not rate an intervention or imply that every topic has equally mature evidence.
New to MoreYears?
Choose an introduction or intervention path—or begin with heart health, cognition, or staying strong and independent. Every step explains why it follows.
Learn
Short guides explain evidence maturity, clinical trials and biomarkers. Editorial standards and the development record remain available in the trust links below.